Lonza and ValenzaBio Enter Clinical Manufacturing Agreement

Lonza will provide drug substance and drug product manufacturing under accelerated timelines for monoclonal antibody treatment at Guangzhou facility.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ValenzaBio, a biopharmaceutical company developing monoclonal antibody therapeutics for autoimmune and inflammatory indications, has entered a manufacturing agreement with Lonza.   This collaboration is aimed at manufacturing VB421, a potential best-in-class anti-insulin-like growth factor 1 receptor (anti-IGF-1R) antibody currently under evaluation for the treatment of thyroid eye disease (TED) and other inflammatory disorders. TED is an autoimmune disease causing eye bulging and vision chang...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters